BioMS Medical's pivotal Multiple Sclerosis trial receives third positive review from Data Safety Monitoring Board

 EDMONTON, CANADA Feb.  7 /CNW/ -

 BioMS Medical Corp.  (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that following the third meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. 

"The DSMB reviewed safety data from our trial, including data from  MRI scans conducted on the first 100 patients dosed in study, who are undergoing an extensive safety analysis as per the trial design," said Kevin Giese, President of BioMS Medical.  "This third positive recommendation by the DSMB members highlights the steady progress being made in advancing our pivotal trial."  

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial.  The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.  The pivotal phase II/III study is now ongoing at trial sites across Canada, the U.K. and Sweden. 

 About BioMS Medical Corp.  -------------------------

 BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies.  BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is currently in a pivotal phase II/III clinical trial across Canada and Europe

 This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS Medical with respect to its performance, business and future events.  Such statements are subject to a number of risks, uncertainties, and assumptions.  Actual results and events may vary significantly.